Incannex Healthcare Inc. Files SEC Form EFFECT

Incannex Healthcare Inc. recently confirmed the completion of a productive pre-investigational new drug meeting with the U.S. Food and Drug Administration (FDA). During the meeting, FDA representatives shared valuable insights on the development program for CannQuit-O, a treatment for opioid use disorder (OUD). The proposed clinical development strategy was also discussed, and the meeting was deemed successful.

CannQuit-O is a unique chewable tablet that combines CBD with an off-patent prescription opioid antagonist and/or partial agonist-antagonist within its formulation. This innovative combination marks Incannex Healthcare Inc.’s continued commitment to advancing cannabinoid and psychedelic medicine in the biotechnology space.

Furthermore, Incannex Healthcare Inc. shared its fiscal first quarter financial results, showcasing ongoing progress and momentum in the company’s efforts to develop novel oral synthetic cannabinoid combination therapeutics and oral synthetic psilocybin treatments. The company remains focused on addressing chronic diseases and significant unmet medical needs, aiming to provide innovative medicines for those in need.

In addition, the company recently appointed Dr. Lou Barbato as Chief Medical Officer, bringing his extensive drug development experience to propel Incannex Healthcare Inc.’s lead clinical-stage programs forward. The future looks bright for the company as it continues to make strides in various therapeutic areas, including obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis.

Incannex Healthcare Inc. is dedicated to advancing its research and development programs, with a strong focus on bringing transformative medicines to market for patients facing challenging medical conditions. The company’s commitment to innovation and patient care drives its mission to make a positive impact on healthcare.